Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.470 -0.010 (-0.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,706,745
Open 2.470
Bid (Size) 2.460 (10)
Ask (Size) 2.480 (9)
Prev. Close 2.480
Today's Range 2.390 - 2.500
52wk Range 2.280 - 10.53
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
From ImmunityBio, Inc.
Via Business Wire

Performance

YTD
-3.9%
-3.9%
1 Month
-10.5%
-10.5%
3 Month
-16.0%
-16.0%
6 Month
-30.4%
-30.4%
1 Year
-49.7%
-49.7%

More News

Read More
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
From ImmunityBio, Inc.
Via Business Wire
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday
Via Benzinga
ImmunityBio to Host Investor Day
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
Via Benzinga
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Via Benzinga
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
Via Benzinga
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
From ImmunityBio, Inc.
Via Business Wire
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
Via Stocktwits
Exposures Product Safety
Garmin Posts Better-Than-Expected Results, Joins SolarEdge Technologies, Compass, Appian And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
From ImmunityBio, Inc.
Via Business Wire
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
From ImmunityBio, Inc.
Via Business Wire
Tesla, Nvidia, GM And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism
Via Stocktwits
Brinker International Posts Upbeat Results, Joins F5, T-Mobile US, Starbucks And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
From ImmunityBio, Inc.
Via Business Wire
IonQ, H&E Equipment Services And ImmunityBio Are Among Top Mid Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
Via Benzinga
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details
Via Benzinga
Exposures Product Safety
Symbotic, DouYu International, Sezzle And Other Big Stocks Moving Higher On Thursday
Via Benzinga

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 2.470
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 04/17/25 04:00 PM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 966.16M
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 966M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback